(Q35953300)

11 August 2017

1 reference

title

What do we know about the mechanism of action of disease-modifying treatments in MS? (English)

1 reference

11 August 2017

1

Hans-Peter Hartung

1 reference

11 August 2017

2

Amit Bar-Or

1 reference

11 August 2017

Yannis Zoukos

3

1 reference

11 August 2017

publication date

1 September 2004

1 reference

11 August 2017

1 reference

11 August 2017

volume

251 Suppl 5

1 reference

11 August 2017

page(s)

v12-v29

1 reference

https://scigraph.springernature.com/pub.10.1007/s00415-004-1504-y

11 August 2017

exact match

0 references

cites work

Inflammation and remyelination in the central nervous system: a tale of two systems

1 reference

https://api.crossref.org/works/10.1007%2FS00415-004-1504-Y

Myelin basic protein‐specific T lymphocyte lines from MS patients and healthy individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-004-1504-Y

Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-004-1504-Y

Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-004-1504-Y

Differential mechanisms of action of interferon-beta and glatiramer aetate in MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-004-1504-Y

Human and murine CD4 T cell reactivity to a complex antigen: recognition of the synthetic random polypeptide glatiramer acetate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-004-1504-Y

Type 2 monocyte and microglia differentiation mediated by glatiramer acetate therapy in patients with multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-004-1504-Y

Mechanisms of action of glatiramer acetate in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-004-1504-Y

IFN-beta-1b inhibits IL-12 production in peripheral blood mononuclear cells in an IL-10-dependent mechanism: relevance to IFN-beta-1b therapeutic effects in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-004-1504-Y

Early development of multiple sclerosis is associated with progressive grey matter atrophy in patients presenting with clinically isolated syndromes

21 January 2018

1 reference

12 December 2020

Sustained immunological effects of Glatiramer acetate in patients with multiple sclerosis treated for over 6 years

1 reference

12 December 2020

Decreased dependence of myelin basic protein-reactive T cells on CD28-mediated costimulation in multiple sclerosis patients. A marker of activated/memory T cells

1 reference

12 December 2020

B-cell immunity in MS.

1 reference

12 December 2020

Molecular mechanisms of axonal damage in inflammatory central nervous system diseases

1 reference

12 December 2020

Contrasting effects of anti-adhesion molecule therapy in experimental allergic encephalomyelitis and Theiler's murine encephalomyelitis

1 reference

12 December 2020

BDNF and gp145trkB in multiple sclerosis brain lesions: neuroprotective interactions between immune and neuronal cells?

1 reference

12 December 2020

Expression of intercellular adhesion molecule-1 and lymphocyte function-associated antigen-1 in the spinal cord of rats during acute experimental allergic encephalomyelitis

1 reference

12 December 2020

Anti-myelin oligodendrocyte glycoprotein B-cell responses in multiple sclerosis

1 reference

12 December 2020

Glatiramer acetate-specific T-helper 1- and 2-type cell lines produce BDNF: implications for multiple sclerosis therapy. Brain-derived neurotrophic factor

1 reference

12 December 2020

Characterization of T cell lines derived from glatiramer-acetate-treated multiple sclerosis patients

1 reference

12 December 2020

Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination

1 reference

12 December 2020

Suppression of experimental allergic encephalomyelitis by a synthetic polypeptide

1 reference

12 December 2020

Augmentation of adoptively transferred experimental allergic encephalomyelitis by administration of a monoclonal antibody specific for LFA-1 alpha

1 reference

12 December 2020

Glatiramer acetate induces a Th2-biased response and crossreactivity with myelin basic protein in patients with MS.

1 reference

12 December 2020

Axonal loss in the pathology of MS: consequences for understanding the progressive phase of the disease

1 reference

12 December 2020

Imaging neuronal and axonal degeneration in multiple sclerosis

1 reference

12 December 2020

Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

1 reference

12 December 2020

Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group

1 reference

12 December 2020

Activated human T cells, B cells, and monocytes produce brain-derived neurotrophic factor in vitro and in inflammatory brain lesions: a neuroprotective role of inflammation?

1 reference

12 December 2020

Identification of macrophage populations expressing tumor necrosis factor-alpha mRNA in acute multiple sclerosis

1 reference

12 December 2020

Immunoregulatory effects of interferon-beta and interacting cytokines on human vascular endothelial cells. Implications for multiple sclerosis autoimmune diseases

1 reference

12 December 2020

Multiple sclerosis: comparison of copolymer-1- reactive T cell lines from treated and untreated subjects reveals cytokine shift from T helper 1 to T helper 2 cells

1 reference

12 December 2020

Beta 2-adrenoceptor involvement in inflammatory demyelination and axonal degeneration in multiple sclerosis.

1 reference

12 December 2020

Treatment of multiple sclerosis with Copaxone (COP): Elispot assay detects COP-induced interleukin-4 and interferon-gamma response in blood cells

1 reference

12 December 2020

Association between cell-mediated demyelination and astrocyte stimulation.

1 reference

12 December 2020

Molecular pathogenesis of multiple sclerosis

1 reference

12 December 2020

Anti-adhesion molecule therapy in experimental autoimmune encephalomyelitis

1 reference

12 December 2020

Immunological update on multiple sclerosis

1 reference

12 December 2020

Cytotoxic T lymphocytes in autoimmune and degenerative CNS diseases.

1 reference

12 December 2020

Inflammation in multiple sclerosis: the good, the bad, and the complex

1 reference

12 December 2020

Interferon beta decreases T cell activation and interferon gamma production in multiple sclerosis

1 reference

12 December 2020

Brain-immune connection: immuno-regulatory properties of CNS-resident cells

1 reference

12 December 2020

Axonal metabolic recovery in multiple sclerosis patients treated with interferon beta-1b.

1 reference

12 December 2020

Glatiramer acetate (copolymer-1)-specific, human T cell lines: cytokine profile and suppression of T cell lines reactive against myelin basic protein

1 reference

12 December 2020

Inhibiting cytokines of the interleukin-12 family: recent advances and novel challenges.

1 reference

12 December 2020

The neuroprotective effect of inflammation: implications for the therapy of multiple sclerosis.

1 reference

12 December 2020

Multiple sclerosis: glatiramer acetate inhibits monocyte reactivity in vitro and in vivo

1 reference

12 December 2020

T-cell recognition of an immuno-dominant myelin basic protein epitope in multiple sclerosis

1 reference

12 December 2020

Glatiramer acetate blocks the activation of THP-1 cells by interferon-gamma

1 reference

12 December 2020

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group

1 reference

12 December 2020

Alpha/beta interferon is a neuronal growth factor

1 reference

12 December 2020

T- and B-cell responses to myelin oligodendrocyte glycoprotein in experimental autoimmune encephalomyelitis and multiple sclerosis

1 reference

12 December 2020

1 reference

12 December 2020

Production of neurotrophins by activated T cells: implications for neuroprotective autoimmunity

1 reference

12 December 2020

Axonal damage in multiple sclerosis: a complex issue in a complex disease

1 reference

12 December 2020

Antimyelin antibodies as a predictor of clinically definite multiple sclerosis after a first demyelinating event

1 reference

12 December 2020

Immunological assay for assessing the efficacy of glatiramer acetate (Copaxone) in multiple sclerosis. A pilot study

1 reference

12 December 2020

Impact of interferon beta-1a on neurologic disability in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

1 reference

12 December 2020

In vitro evidence that subcutaneous administration of glatiramer acetate induces hyporesponsive T cells in patients with multiple sclerosis

1 reference

12 December 2020

The expression profile of matrix metalloproteinases (MMPs) and their inhibitors (TIMPs) in lesions and normal appearing white matter of multiple sclerosis

1 reference

12 December 2020

Immunotherapy of multiple sclerosis: where are we? Where should we go?

1 reference

12 December 2020

Treatment of multiple sclerosis: recent trials and future perspectives

1 reference

12 December 2020

Multiple sclerosis: deeper understanding of its pathogenesis reveals new targets for therapy.

1 reference

12 December 2020

Evidence for widespread axonal damage at the earliest clinical stage of multiple sclerosis.

1 reference

12 December 2020

Therapeutic approaches in multiple sclerosis: lessons from failed and interrupted treatment trials

1 reference

12 December 2020

Increased CD80(+) B cells in active multiple sclerosis and reversal by interferon beta-1b therapy

1 reference

12 December 2020

Increased frequency of interleukin 2-responsive T cells specific for myelin basic protein and proteolipid protein in peripheral blood and cerebrospinal fluid of patients with multiple sclerosis

1 reference

12 December 2020

Treatment of multiple sclerosis with copolymer-1 (Copaxone): implicating mechanisms of Th1 to Th2/Th3 immune-deviation.

1 reference

12 December 2020

Magnetic resonance studies of abnormalities in the normal appearing white matter and grey matter in multiple sclerosis

1 reference

12 December 2020

Distribution of plaques in seventy autopsy cases of multiple sclerosis in the United States

1 reference

12 December 2020

Glatiramer acetate-specific T cells in the brain express T helper 2/3 cytokines and brain-derived neurotrophic factorin situ

1 reference

12 December 2020

Matrix metalloproteinases in inflammatory demyelination: targets for treatment

1 reference

12 December 2020

Genetics of multiple sclerosis

1 reference

12 December 2020

Immunomodulation in multiple sclerosis: from immunosuppression to neuroprotection

1 reference

12 December 2020

Immunocytochemical characterisation of the immune reaction in the central nervous system in multiple sclerosis. Possible role for microglia in lesion growth.

1 reference

12 December 2020

Specific inhibition of the T-cell response to myelin basic protein by the synthetic copolymer Cop 1

1 reference

12 December 2020

Long-term therapy with glatiramer acetate in multiple sclerosis: effect on T-cells

1 reference

12 December 2020

Mechanisms of immunomodulation by glatiramer acetate

1 reference

12 December 2020

Lymphocyte targeting of the central nervous system: a review of afferent and efferent CNS-immune pathways

1 reference

12 December 2020

Glatiramer acetate-reactive T cells produce brain-derived neurotrophic factor

1 reference

12 December 2020

Genetic aspects of multiple sclerosis

1 reference

12 December 2020

Expression of specific chemokines and chemokine receptors in the central nervous system of multiple sclerosis patients

1 reference

12 December 2020

Interferon-? therapy for multiple sclerosis induces reciprocal changes in interleukin-12 and interleukin-10 production

1 reference

12 December 2020

Expression and modulation of IFN-gamma-inducible chemokines (IP-10, Mig, and I-TAC) in human brain endothelium and astrocytes: possible relevance for the immune invasion of the central nervous system and the pathogenesis of multiple sclerosis

1 reference

12 December 2020

New concepts in the immunopathogenesis of multiple sclerosis

1 reference

12 December 2020

Enhanced expression of MMP-7 and MMP-9 in demyelinating multiple sclerosis lesions.

1 reference

12 December 2020

Risk factors of multiple sclerosis: a case-control study

1 reference

12 December 2020

The adhesion molecule and cytokine profile of multiple sclerosis lesions

1 reference

12 December 2020

Inflammatory central nervous system demyelination: correlation of magnetic resonance imaging findings with lesion pathology.

1 reference

12 December 2020

The multiple sclerosis trait: a disease waiting to happen?

1 reference

12 December 2020

Interferon beta-1b decreases the migration of T lymphocytes in vitro: effects on matrix metalloproteinase-9.

1 reference

12 December 2020

Interferon beta in the treatment of multiple sclerosis: mechanisms of action

1 reference

12 December 2020

Novel IL-12 family members shed light on the orchestration of Th1 responses

1 reference

12 December 2020

T cell immunity to copolymer 1 confers neuroprotection on the damaged optic nerve: possible therapy for optic neuropathies

1 reference

12 December 2020

Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12

1 reference

12 December 2020

Interleukin-1beta promotes oligodendrocyte death through glutamate excitotoxicity

1 reference

12 December 2020

The enigma of multiple sclerosis: inflammation and neurodegeneration cause heterogeneous dysfunction and damage

1 reference

12 December 2020

Suppression of experimental autoimmune encephalomyelitis by selective blockade of encephalitogenic T-cell infiltration of the central nervous system

1 reference

12 December 2020

Direct impact of T cells on neurons revealed by two-photon microscopy in living brain tissue.

1 reference

12 December 2020

Intrathecal administration of antibodies against LFA-1 and against ICAM-1 suppresses experimental allergic encephalomyelitis in rats.

1 reference

12 December 2020

Interferon beta-1b inhibits gelatinase secretion and in vitro migration of human T cells: a possible mechanism for treatment efficacy in multiple sclerosis

1 reference

12 December 2020

Multiple sclerosis: Fas signaling in oligodendrocyte cell death

1 reference

12 December 2020

Spatial mapping of T2 and gadolinium-enhancing T1 lesion volumes in multiple sclerosis: evidence for distinct mechanisms of lesion genesis?

1 reference

12 December 2020

VLA-4 expression on peripheral blood lymphocytes is downregulated after treatment of multiple sclerosis with interferon beta

1 reference

12 December 2020

Axonal degeneration and progressive neurologic disability in multiple sclerosis

1 reference

12 December 2020

Factors modifying the migration of lymphocytes across the blood-brain barrier

1 reference

12 December 2020

Inflammation and degeneration in multiple sclerosis

1 reference

12 December 2020

beta-Interferon regulates the immunomodulatory activity of neonatal rodent microglia

1 reference

12 December 2020

Interferon-beta inhibits activated leukocyte migration through human brain microvascular endothelial cell monolayer.

1 reference

12 December 2020

Axonal damage in acute multiple sclerosis lesions.

1 reference

12 December 2020

The Expression of Tissue-type Plasminogen Activator, Matrix Metalloproteases and Endogenous Inhibitors in the Central Nervous System in Multiple Sclerosis

1 reference

12 December 2020

Interferon-gamma modulates human oligodendrocyte susceptibility to Fas-mediated apoptosis

1 reference

12 December 2020

Mechanisms of inflammation in MS tissue: adhesion molecules and chemokines

1 reference

12 December 2020

Multiple paradigm shifts in multiple sclerosis

1 reference

12 December 2020

Immunological effects of in vivo interferon-beta1b treatment in ten patients with multiple sclerosis: a 1-year follow-up

1 reference

12 December 2020

Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain

1 reference

12 December 2020

Metalloproteinases in biology and pathology of the nervous system.

1 reference

12 December 2020

Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. The IFNB Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group

1 reference

12 December 2020

Temporal variations of adhesion molecules and matrix metalloproteinases in the course of MS.

1 reference

12 December 2020

Protection against experimental allergic encephalomyelitis.

1 reference

12 December 2020

The role of oxidative stress in the pathogenesis of multiple sclerosis: the need for effective antioxidant therapy

1 reference

12 December 2020

Both anti-CD11a (LFA-1) and anti-CD11b (MAC-1) therapy delay the onset and diminish the severity of experimental autoimmune encephalomyelitis

1 reference

12 December 2020

Current disease-modifying therapies in multiple sclerosis

1 reference

12 December 2020

Autoimmune T cells protect neurons from secondary degeneration after central nervous system axotomy

1 reference

12 December 2020

Glutamate excitotoxicity--a mechanism for axonal damage and oligodendrocyte death in Multiple Sclerosis?

1 reference

12 December 2020

Disease-modifying therapies in multiple sclerosis: an update on recent and ongoing trials and future strategies

1 reference

12 December 2020

The Janus face of CNS-directed autoimmune response: a therapeutic challenge.

1 reference

12 December 2020

Tumour necrosis factor alpha mRNA expression in early multiple sclerosis lesions: correlation with demyelinating activity and oligodendrocyte pathology

1 reference

12 December 2020

Glatiramer acetate (Copaxone) induces degenerate, Th2-polarized immune responses in patients with multiple sclerosis

1 reference

12 December 2020

Glatiramer acetate-reactive peripheral blood mononuclear cells respond to multiple myelin antigens with a Th2-biased phenotype.

1 reference

12 December 2020

Biology of disease. Analysis of autoimmune demyelination: its impact upon multiple sclerosis

1 reference

12 December 2020

Interferon beta induces interleukin-10 expression: relevance to multiple sclerosis.

1 reference

12 December 2020

Clonal expansion and persistence of human T cells specific for an immunodominant myelin basic protein peptide

1 reference

12 December 2020

10.1007/S00415-004-1504-Y

Identifiers

DOI

1 reference

11 August 2017

1 reference